Anavex rises on US patent for insomnia, anxiety treatment

Anavex Life Sciences

22/11/2023 15:21

** Drugmaker Anavex Life Sciences'  AVXL.O  shares rise 1.8%
to $6.84
    ** Company says U.S. Patent and Trademark Office issued
patent for its drug blarcamesine as a treatment for insomnia,
anxiety or agitation
    ** Blarcamesine is currently being evaluated for treatment
of Alzheimer's disease 
    ** AVXL says new patent expands on existing patent coverage
and expected to be valid until July 2037
    ** Including session's move, stock down 26.4% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))